As we approach the opening bell, here’s a snapshot of the US pre-market action. The major indices are relatively calm:

• S&P 500 (ES): Flat
• Nasdaq (NQ): +0.1%
• Russell 2000 (RTY): +0.7%
• Dow Jones (YM): Flat

While the broader market remains steady, earnings reports are driving significant stock-specific movements.

Earnings Highlights:

• Morgan Stanley ($MS) +3.8%: The firm outperformed expectations on both earnings per share (EPS) and revenue, thanks to robust Wealth Management, Investment Banking, and trading revenue.
• U.S. Bancorp ($USB) +3%: Topped estimates for both EPS and net interest income (NII), though net charge-offs slightly exceeded expectations.
• Abbott Laboratories ($ABT) -0.7%: Despite beating Q3 earnings estimates and issuing upbeat Q4 and full-year EPS guidance, organic sales (excluding COVID test kits) missed the mark. The company announced a $7 billion share buyback program.
• Citizens Financial Group ($CFG) -1.9%: Q3 revenue missed expectations, although profit aligned with forecasts. The company remains optimistic about strong growth heading into 2025.
• Prologis ($PLD) +1.1%: Surpassed expectations on profit, revenue, and core funds from operations (FFO) per share.
• United Airlines ($UAL) +1.5%: Delivered a beat on both the top and bottom lines while also announcing a $1.5 billion share buyback program.
• Interactive Brokers ($IBKR) -2.6%: Missed on EPS but beat on revenue.

Stock-Specific News:

• Intel ($INTC) -1.1%: Qualcomm has postponed its acquisition decision of Intel assets until after the US elections. Additionally, China has called for a risk examination of Intel products.
• Cisco Systems ($CSCO) +1.9%: Citi upgraded the stock to “Buy” with a price target of $62 (previously $52), citing growth potential in the expanding ethernet AI market.
• Carrier Global ($CARR) -1%: Downgraded to “Equal Weight” by Stephens, despite raising the price target to $85 from $75, noting that the share price already reflects the company’s transformation success.
• Novavax ($NVAX) -17.5%: Took a significant hit after the FDA placed a clinical hold on its COVID-19 and influenza vaccine candidates.
• Novocure ($NVCR) +20.3%: Surged after the FDA approved its Optune Lua wearable device for treating metastatic non-small cell lung cancer.

Today’s pre-market highlights underscore the influence of earnings beats and misses on individual stocks, while broader market indices remain relatively unchanged. Keep an eye on continued developments in the vaccine and tech sectors, as well as key upgrades and downgrades that could shift market sentiment throughout the day.